News

Hosted on MSN2mon
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation ...
pharmaphorum1d
GSK asthma hope depemokimab works in second indication
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...
Investing1mon
GSK’s depemokimab accepted by FDA for asthma, CRSwNP indications
According to InvestingPro analysis, GSK currently appears undervalued, suggesting potential upside for investors interested in this development. The applications pertain to the use of depemokimab as ...
Nasdaq1mon
GSK: Depemokimab Shows Significant Improvements For CRSwNP Patients In Phase III Trials
(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...
Yahoo Finance24d
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
GSK plc GSK announced that the FDA has approved ... Other planned launches include Blenrep (for multiple myeloma), depemokimab (chronic rhinosinusitis with nasal polyps and asthma with type ...
FiercePharma24d
GSK ushers in new UTI antibiotic with FDA nod for first-in-class Blujepa
GSK is opening the door to a new era in urinary ... plus a new launch for biologic depemokimab. All five should help the company achieve its recently increased 2031 sales goal of more than 40 ...